L.I.A. Pure Capital 5.0% position in Clearmind Medicine (CMND) detailed

Rhea-AI Filing Summary

L.I.A. Pure Capital Ltd. filed an amendment to a Schedule 13G reporting beneficial ownership in Clearmind Medicine Inc. The filing states 108,720 Common Shares, representing 5.0% of the class based on 2,088,806 shares outstanding as of the reporting date. The position consists of 20,470 currently held Common Shares, 93,231 shares issuable upon conversion of a convertible promissory note at a $1.25 floor conversion price, and 229,000 shares exercisable under a pre-funded warrant; exercise/conversion are subject to a 4.99% beneficial ownership blocker. The amendment is signed by Kfir Silberman as CEO on 03/16/2026.

Insights

Corporate Governance Analyst

Schedule 13G/A updates a reported 5.0% stake and notes ownership limits.

The filing breaks down beneficial ownership into direct shares, convertible-note issuable shares assuming a $1.25 conversion floor, and pre-funded warrant exercise shares. The blocker provision limiting ownership to 4.99% is expressly stated and conditions conversion/exercise.

Future disclosures should clarify timing of conversion/exercise; current filings show a capped potential stake rather than immediate voting control beyond the stated 5.0% figure.

Capital Markets Specialist

Position mixes direct holdings and exercisable/convertible instruments that create potential future dilution.

The reported 108,720 shares and supporting instrument counts (93,231 conversion shares; 229,000 warrant shares) indicate contractual pathways to acquire additional shares within 60 days as described. The conversion price and pre-funded warrant structure are explicit in the filing.

Because the instrument exercises are subject to a 4.99% blocker, actual near-term share issuance depends on anti‑dilution mechanics and holder decisions; cash‑flow treatment is not described in the excerpt.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 2)

Clearmind Medicine Inc.

(Name of Issuer)

Common Shares, no par value per share

(Title of Class of Securities)

(CUSIP Number)

02/09/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP No.

1

Names of Reporting Persons

L.I.A. Pure Capital Ltd.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

ISRAEL

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 108,720.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 108,720.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

108,720.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.0 %

12

Type of Reporting Person (See Instructions)

CO

Comment for Type of Reporting Person: *Percentage calculated based on 2,088,806 common shares, no par value per share, of Clearmind Medicine Inc. (the "Issuer") issued and outstanding as of the reporting date, which amount was provided to the Reporting Person by the Issuer.

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Clearmind Medicine Inc.
(b)	Address of issuer's principal executive offices: 101 - 1220 West 6th Avenue, Vancouver, BRITISH COLUMBIA, CANADA, V6H1A5.
Item 2.
(a)	Name of person filing: L.I.A. Pure Capital Ltd.
(b)	Address or principal business office or, if none, residence: 20 Raoul Wallenberg Street, Tel Aviv, Israel 6971916
(c)	Citizenship: Israel
(d)	Title of class of securities: Common Shares, no par value per share
(e)	CUSIP No.:
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: See items 5-11 of the cover pages hereto for beneficial ownership, percentage of class and dispositive power of the Reporting Person, which is incorporated herein. Amount beneficially owned by the Reporting Person consists of (i) 20,470 Common Shares and (ii) 93,231 Common Shares issuable upon the conversion of a convertible promissory note (the "Note") in the aggregate principial amount of $116,538.50, including the accrued interest thereon, assuming a conversion price of $1.25, the floor price of the Note, which may be acquired by the Reporting Person within 60 days of the date hereof through the conversion of the Note, and (iii) 229,000 Common Shares which may be acquired by the Reporting Person within 60 days of the date hereof through the exercise of a pre-funded warrant (the "Warrant"). The Note and the Warrant each include a blocker provision under which the Reporting Person does not have the right to exercise the Warrant or convert the Note, respectively, to the extent (but only to the extent) that such exercise or conversion would result in beneficial ownership by the Reporting Person, together with the Reporting Person's affiliates, and any other persons acting as a group together with the Reporting Person or any of the Reporting Person's affiliates, of more than 4.99% of the Ordinary Shares.
(b)	Percent of class: See items 5-11 of the cover pages hereto for beneficial ownership, percentage of class and dispositive power of the Reporting Person, which is incorporated herein.
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: See items 5-11 of the cover pages hereto for beneficial ownership, percentage of class and dispositive power of the Reporting Person, which is incorporated herein.
	(ii) Shared power to vote or to direct the vote: See items 5-11 of the cover pages hereto for beneficial ownership, percentage of class and dispositive power of the Reporting Person, which is incorporated herein.
	(iii) Sole power to dispose or to direct the disposition of: See items 5-11 of the cover pages hereto for beneficial ownership, percentage of class and dispositive power of the Reporting Person, which is incorporated herein.
	(iv) Shared power to dispose or to direct the disposition of: See items 5-11 of the cover pages hereto for beneficial ownership, percentage of class and dispositive power of the Reporting Person, which is incorporated herein.
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

L.I.A. Pure Capital Ltd.

Signature:	/s/ Kfir Silberman
Name/Title:	Kfir Silberman/Chief Executive Officer
Date:	03/16/2026

FAQ

What stake does L.I.A. Pure Capital report in Clearmind (CMND)?

L.I.A. Pure Capital reports beneficial ownership of 108,720 Common Shares, equal to 5.0% of shares based on 2,088,806 outstanding as of the reporting date. The filing itemizes direct shares and instrument‑based potential shares.

How is the 5.0% ownership composed in the Schedule 13G/A for CMND?

The position comprises 20,470 directly held Common Shares, 93,231 shares issuable upon conversion of a note at a $1.25 floor, and 229,000 shares exercisable under a pre‑funded warrant, per the filing's breakdown.

Does the filing limit conversion or exercise of instruments for CMND?

Yes. Both the Note and the Warrant include a blocker provision preventing conversion or exercise to the extent it would cause beneficial ownership to exceed 4.99% for the Reporting Person and related parties.

Are the convertible note and warrant convertible/exercisable immediately for CMND?

The filing states the shares may be acquired within 60 days through conversion or exercise, conditioned by instrument terms and the 4.99% beneficial ownership blocker described in the amendment.

Who signed the Schedule 13G/A amendment for CMND and when?

The amendment is signed by Kfir Silberman, Chief Executive Officer of the reporting entity, with the signature dated 03/16/2026, as shown on the cover page included in the excerpt.